<DOC>
	<DOCNO>NCT01488877</DOCNO>
	<brief_summary>PF-03882845 compound propose treatment type 2 diabetic nephropathy . The primary purpose trial evaluate safety tolerability , pharmacokinetics pharmacodynamics multiple dos PF-03882845 population .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy</brief_title>
	<detailed_description>This study terminate 12-Sep-2012 ; decision make due poor recruitment overall business strategy . The study terminate safety reason lack efficacy .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Males and/or Females 1865 year , inclusive . Body mass index 18.5 45.4 kg/m2 screening , inclusive . body weight equal great 110 lb . Have type 2 diabetes mellitus . On stable dose antidiabetic antihypertensive medication prior screen . Recent evidence medical history unstable concurrent disease . Cardiovascular event within 3 month prior screen . History renal transplant . History hospitalization acute kidney injury acute kidney dialysis within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 diabetes mellitus . albuminuria .</keyword>
</DOC>